ARE February 2026 Options Begin Trading

Alexandria Real Estate Equities (ARE) is highlighted for two option strategies around the current share price of $48.43: a sell-to-open $45 put bid at $0.60 which nets an effective cost basis of $44.40 and carries a 65% probability of expiring worthless (1.33% return on cash, 7.60% annualized YieldBoost), and a covered-call using the $50 strike bid at $0.40 that would produce a 4.07% total return if called at the February 2026 expiry with a 57% chance of expiring worthless (0.83% premium, 4.71% annualized YieldBoost). Implied volatility is 49% on the put and 42% on the call versus a trailing 12‑month volatility of 41%; figures exclude broker commissions and underscore tradeoffs between yield generation and capped upside.

Analysis

Market structure: The option quotes imply asymmetric market positioning—puts (IV 49%) are priced ~8pt above realized vol (41%), signaling paid-for downside protection and that market participants expect higher left-tail risk for ARE (current price $48.43). Winners: options sellers collecting yield (cash-secured put sellers, covered-call sellers) and long-biotech REIT holders if rents/tenants hold. Losers: long-duration, rate-sensitive REIT holders if real rates rise; pricing power for life-science landlords is intact short-term but vulnerable to tenant funding shocks.

Risk assessment: Tail risks include a biotech funding shock or a >100bp sustained rise in real yields that could compress NAVs 8–12% within 3–12 months; tenant-cluster concentration and lease expirations are second-order risks that can amplify vacancies. Immediate (days) risk is IV re-pricing around macro prints; short-term (weeks–months) risk is 10–20% price moves from rate or credit events; long-term (quarters) depends on lease roll economics and biotech cap-ex penditures.

Trade implications: Direct plays: prefer structured premium strategies over naked exposure—cash-secured $45 puts (Feb 2026) or $45/$40 bull-put spreads to collect ~1.3% yieldboost with defined downside. Pair trade: long ARE vs short VNQ (equal-dollar) to isolate life-science out/underperformance. Time entry within next 10 trading days, size 1–3% portfolio per trade, and set stop-loss at 10% adverse move or IV spike >10 vol points.

Contrarian angles: Consensus overstates the structural vacancy risk—IV skew exceeds realized vol, so selling premium is arguably underpriced if tenant fundamentals hold; however, assignment risk means sellers may be forced to hold equity into a higher-rate regime. Historical parallel: 2020/21 life-science rebounds showed outsized returns when funding resumed; unintended consequence is forced long equity concentration if selling puts without hedges.

Key Decisions for Investors

• Sell cash-secured ARE Feb‑2026 $45 put for $0.60 (net effective cost basis $44.40) sized 2% of portfolio; cap assignment risk by buying back if ARE drops >10% from current ($<43.60) or implied vol >55%.
• Establish a conservative $45/$40 bull-put spread (Feb‑2026) instead of naked put to limit max loss to $5.00/share width minus premium (approx cap loss ~9–10%); allocate 1–2% capital and enter within 10 trading days.
• Buy ARE up to a 3% position and sell Feb‑2026 $50 covered calls for $0.40 to generate ~4.1% upside+premium return; roll or close if ARE >$55 within 90 days or if 10‑yr Treasury rises >50bps.
• Implement a 1–2% long ARE vs 1–2% short VNQ pair to express life‑science idiosyncratic strength; exit if VNQ outperforms ARE by >5% over 60 days or if macro volatility (MOVE) spikes >20%.